US Patent Issued to I-Mab Biopharma US, ABL Bio on March 17 for "Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof" (South Korean, Chinese Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,313, issued on March 17, was assigned to I-Mab Biopharma US Ltd. (Gaithersburg, Md.) and ABL Bio Inc. (Seongnam-Si, South Korea).

"Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof" was invented by Wenqing Jiang (Shanghai), Lei Fang (Shanghai), Zhengyi Wang (Shanghai), Bingshi Guo (Shanghai), Eunyoung Park (Seongnam-Si, South Korea), Eunsil Sung (Seongnam-Si, South Korea) and Byungje Sung (Seongnam-Si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, ...